Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Analyst Ratings
Hold
6 Buy
19 Hold
5 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SRPT Stock 12 Month Forecast
Average Price Target
$24.52
▲(21.27% Upside)
| Highest Price Target$80.00 | Average Price Target$24.52 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bernstein
―
Hold
―
Reiterated
08/22/25
Mizuho Securities
$20.06→$19
Hold
-6.03%
Downside
Reiterated
08/22/25
Barclays
$22
Hold
8.80%
Upside
Reiterated
08/21/25
Morgan Stanley
$20
Hold
-1.09%
Downside
Reiterated
08/21/25
Bank of America Securities
$17→$16
Sell
-20.87%
Downside
Reiterated
08/21/25
TR | OpenAI - 4o
$20→$20.5
Hold
1.38%
Upside
Reiterated
08/21/25
Citi
$14
Sell
-30.76%
Downside
Initiated
08/20/25
Deutsche Bank
$6→$12
Sell
-40.65%
Downside
Reiterated
08/15/25
Leerink Partners
―
Hold
―
Reiterated
08/14/25
Hold Rating on Sarepta Therapeutics Amid Strategic Sale and siRNA Data UncertaintyWe view Sarepta's (SRPT, MP) decision to sell its entire stake in Arrowhead (ARWR, MP, Foroohar) as a prudent move to shore up the balance sheet; however, we think more work needs to be done, and wonder what the readthrough (if any) is for the upcoming siRNA data in 2H25. As part of the agreement with ARWR that was announced last year (here), SRPT made a $325M equity investment in ARWR at $27.25 per share (11,926,301 shares). The agreement became effective on and was subject to a 180-day lock-up period. Thus, considering the recent turmoil with the Elevidys program, we knew a potential sale of the equity stake was possible (especially considering our concerns regarding the balance sheet [B/S] and the company's ability to pay the 2027 convert). As disclosed yesterday, SRPT sold 9,265,312 shares of ARWR stock and expects to receive at least $174M in gross proceeds.
H.C. Wainwright
$5
Sell
-75.27%
Downside
Reiterated
08/14/25
TD Cowen
$17
Hold
-15.92%
Downside
Reiterated
08/11/25
Evercore ISI
$19
Hold
-6.03%
Downside
Reiterated
08/11/25
Jefferies
$35
Buy
73.10%
Upside
Reiterated
08/11/25
Freedom Capital Markets
$14→$37
Buy
82.99%
Upside
Upgraded
08/11/25
Wells Fargo
$50
Buy
147.28%
Upside
Reiterated
08/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
―
Hold
―
Reiterated
08/22/25
Mizuho Securities
$20.06→$19
Hold
-6.03%
Downside
Reiterated
08/22/25
Barclays
$22
Hold
8.80%
Upside
Reiterated
08/21/25
Morgan Stanley
$20
Hold
-1.09%
Downside
Reiterated
08/21/25
Bank of America Securities
$17→$16
Sell
-20.87%
Downside
Reiterated
08/21/25
TR | OpenAI - 4o
$20→$20.5
Hold
1.38%
Upside
Reiterated
08/21/25
Citi
$14
Sell
-30.76%
Downside
Initiated
08/20/25
Deutsche Bank
$6→$12
Sell
-40.65%
Downside
Reiterated
08/15/25
Leerink Partners
―
Hold
―
Reiterated
08/14/25
Hold Rating on Sarepta Therapeutics Amid Strategic Sale and siRNA Data UncertaintyWe view Sarepta's (SRPT, MP) decision to sell its entire stake in Arrowhead (ARWR, MP, Foroohar) as a prudent move to shore up the balance sheet; however, we think more work needs to be done, and wonder what the readthrough (if any) is for the upcoming siRNA data in 2H25. As part of the agreement with ARWR that was announced last year (here), SRPT made a $325M equity investment in ARWR at $27.25 per share (11,926,301 shares). The agreement became effective on and was subject to a 180-day lock-up period. Thus, considering the recent turmoil with the Elevidys program, we knew a potential sale of the equity stake was possible (especially considering our concerns regarding the balance sheet [B/S] and the company's ability to pay the 2027 convert). As disclosed yesterday, SRPT sold 9,265,312 shares of ARWR stock and expects to receive at least $174M in gross proceeds.
H.C. Wainwright
$5
Sell
-75.27%
Downside
Reiterated
08/14/25
TD Cowen
$17
Hold
-15.92%
Downside
Reiterated
08/11/25
Evercore ISI
$19
Hold
-6.03%
Downside
Reiterated
08/11/25
Jefferies
$35
Buy
73.10%
Upside
Reiterated
08/11/25
Freedom Capital Markets
$14→$37
Buy
82.99%
Upside
Upgraded
08/11/25
Wells Fargo
$50
Buy
147.28%
Upside
Reiterated
08/11/25
Best Analysts Covering Sarepta Therapeutics
1 Month
xxx
Success Rate
23/38 ratings generated profit
Average Return
+5.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.53% of your transactions generating a profit, with an average return of +5.57% per trade.
3 Months
xxx
Success Rate
21/38 ratings generated profit
Average Return
+6.22%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.26% of your transactions generating a profit, with an average return of +6.22% per trade.
1 Year
Success Rate
19/38 ratings generated profit
Average Return
+7.74%
reiterated a buy rating last month
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.74% per trade.
2 Years
xxx
Success Rate
16/38 ratings generated profit
Average Return
+5.68%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.11% of your transactions generating a profit, with an average return of +5.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SRPT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
47
53
49
44
29
Buy
8
9
10
10
7
Hold
15
23
38
80
90
Sell
3
1
1
11
16
Strong Sell
0
0
1
4
7
total
73
86
99
149
149
Each month's total comprises the sum of three months' worth of ratings.
SRPT Financial Forecast
SRPT Stock Forecast FAQ
What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 24.52.
What is SRPT’s upside potential, based on the analysts’ average price target?
Sarepta Therapeutics has 21.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SRPT a Buy, Sell or Hold?
Sarepta Therapeutics has a consensus rating of Hold which is based on 6 buy ratings, 19 hold ratings and 5 sell ratings.
What is Sarepta Therapeutics’s price target?
The average price target for Sarepta Therapeutics is 24.52. This is based on 30 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents 21.27% Increase from the current price of $20.22.
The highest analyst price target is $80.00 ,the lowest forecast is $5.00. The average price target represents 21.27% Increase from the current price of $20.22.
What do analysts say about Sarepta Therapeutics?
Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 30 Wall Streets Analysts.
How can I buy shares of SRPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.